Conditions: Benign Prostatic Hyperplasia
Keywords: Prostate BPH Benign Prostatic Hyperplasia BPH-LUTS LUTS Phosphodiesterase Inhibitors tadalafil alpha blockers
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 318
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such as urinary frequency, urgency, and a feeling that the bladder is not completely emptied after urination).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Tadalafil intervention 2: Placebo
Intervention descriptions: intervention 1: 5 mg taken by mouth once daily for 12 weeks intervention 2: By mouth once daily for 12 weeks

Protocol document: